Business / Finance

RSS

ERES IV acquires a majority stake in Oncodesign Services

Oncodesign Services, a leading Contract Research Organization (CRO) specializing in drug discovery and preclinical services in oncology and immuno-inflammation, and Elyan Partners announce the completion of the acquisition of a majority stake in Oncodesign Services by ERES IV, representing 61.58% of its share capital, from its main shareholders, including Mr. Philippe Genne, Founder of Oncodesign Services, as well as certain key shareholders and several managers and minority shareholders, following the entry into exclusive negotiations on June 30, 2022.

From Oncodesign Services 3 Feb 2023

Ingenza collaborates with Amplifica to advance novel alopecia treatments

Industrial biotech specialist Ingenza is delighted to announce that it is collaborating with clinical-stage biopharmaceutical company Amplifica Holdings Group, Inc. to develop an innovative treatment to address androgenic alopecia.

From Ingenza Ltd 23 Jan 2023

Beckman Coulter Life Sciences completes first phase of Colorado Research and Development Hub with grand opening of $10 million Loveland offices

Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, further strengthens its commitment to the greater Loveland, Colorado community with the completion of the first phase of its new research and development hub.

From Beckman Coulter Life Sciences 20 Jan 2023

2023 EVIDENT Organoid Conference to share the latest organoid innovations

Building on the momentum from last year’s conference, the 2023 Evident Organoid Conference will highlight organoid innovations that are poised to accelerate progress in drug research and discovery.

From Evident Corporation - Life Sciences 18 Jan 2023

TTP introduces Cellular Origins, a TTP Company focussed on delivering scalable manufacture of cell and gene therapies

New company created to enable commercial manufacture of new cell and gene therapies.

From TTP plc 17 Jan 2023

Optibrium appoints Steve Yemm as Chief Commercial Officer

New role will lead global commercial strategy and development as Optibrium continues to scale its drug discovery technologies and team.

From Optibrium Ltd. 17 Jan 2023

The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system

Expansion of five-year collaboration broadens established Organ-on-a-chip research demonstrating advanced performance of the PhysioMimix MPS.

From CN-Bio 17 Jan 2023

Generative AI approach unlocks path to accelerated antibody drug creation for novel therapeutic targets

A recent study used generative AI models to develop de novo design antibodies against three distinct targets in a zero-shot fashion.

11 Jan 2023

Sustainable Laboratory Product of the Year - CellDrop Automated Cell Counter

The DeNovix CellDrop™ Automated Cell Counter has been awarded Sustainable Laboratory Product of the Year in the SelectScience® Scientists’ Choice Awards®.

From DeNovix Inc. 11 Jan 2023

Evosep receives strategic investment from Novo Holding A/S to accelerate its effort on clinical proteomics

Evosep today announced that Novo Holdings A/S has become a minority shareholder in Evosep Aps with a US$ 40m investment to further Evosep’s technology and application portfolio for clinical proteomics.

From Evosep 10 Jan 2023

Complete Genomics Launches Full Sequencing Platforms at Biotech Showcase™ 2023

...

From MGI 10 Jan 2023

Vector BioPharma and iBET collaborate to develop high-throughput analytical methods and scalable processes for gene delivery

Collaboration set to develop and implement high-throughput analytical methods in support of Vector BioPharma’s CMC (chemistry, manufacturing and controls) development.

From Vector BioPharma 10 Jan 2023

Astrea Bioseparations acquires Delta Precision Ltd, a leading manufacturer of chromatography columns for biomanufacturing

Astrea Bioseparations, a leading provider of high-quality bioseparation and purification technologies, announced today the acquisition of Delta Precision Ltd., a premier manufacturer of advanced chromatography columns for the biotechnology and pharmaceutical industries.

10 Jan 2023

Ubiquigent appoints Dr Xavier Jacq to Scientific Advisory Board

Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced the appointment of Dr Xavier Jacq to its Scientific Advisory Board (SAB).

10 Jan 2023

Cerba Research is officially a member of Hong Kong Bio-Med Innotech Association (HKBMIA)

Cerba Research announces membership of HKBMIA to act as an advisor on speciality testing and routine clinical trials testing to advance research and health while supporting Asia pacific healthcare companies develop new therapeutics.

From Cerba Research 6 Jan 2023

PhoreMost and Boehringer Ingelheim enter multi-project drug discovery collaboration

PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a multi-project drug discovery collaboration with Boehringer Ingelheim, one of the world-leading pharmaceutical companies developing innovative therapies for diseases with unsatisfactory treatments.

5 Jan 2023

RQM+ Launches Clinical Trial Services

RQM+ today announced the launch of its clinical trial services division to complete its full complement of MedTech contract research organization (CRO) services.

From RQM+ 4 Jan 2023

Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company

Berkeley Lights (Nasdaq: BLI) and IsoPlexis (Nasdaq: ISO) today announced a definitive agreement under which Berkeley Lights will acquire IsoPlexis in an all-stock transaction valued at $57.8 million.

From Bruker Cellular Analysis 3 Jan 2023

Fujifilm announces asset purchase agreement with Inspirata, Inc. to acquire the company’s digital pathology business

FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced the company has entered into an asset purchase agreement to acquire the global digital pathology business of Tampa, Florida-based Inspirata, Inc. Upon completion of this agreement, Inspirata's Dynamyx® digital pathology technology, employees and customers will become part of Fujifilm.

From FUJIFILM Corporation 20 Dec 2022

CN Bio appoints Dr Paul Brooks as Chief Executive Officer

CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced the appointment of Dr Paul Brooks, formerly the Company’s Chief Business Officer, to the position of CEO with immediate effect. Former CEO, Dr David Hughes, will continue to work with the company in a consultative role within the Company’s Scientific Advisory Board.

From CN-Bio 19 Dec 2022